Lyell Immunopharma, Inc. (NASDAQ:LYEL – Get Free Report) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $40.8571.
LYEL has been the topic of several recent analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $44.00 price objective on shares of Lyell Immunopharma in a research report on Friday. B. Riley Financial started coverage on shares of Lyell Immunopharma in a report on Wednesday, July 22nd. They issued a “buy” rating and a $44.00 target price on the stock. Citizens Jmp reaffirmed a “market outperform” rating and issued a $34.00 price target on shares of Lyell Immunopharma in a report on Monday, June 15th. Stifel Nicolaus started coverage on Lyell Immunopharma in a research report on Thursday, August 6th. They issued a “buy” rating and a $36.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Friday, July 17th.
Get Our Latest Stock Analysis on LYEL
Lyell Immunopharma Stock Performance
Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($1.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.94) by $0.02. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. The company had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.00 million. On average, analysts predict that Lyell Immunopharma will post -7.2 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC grew its position in shares of Lyell Immunopharma by 194.8% during the 1st quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock worth $2,335,000 after buying an additional 76,921 shares in the last quarter. MWG Caph Ltd purchased a new position in Lyell Immunopharma in the fourth quarter valued at about $31,030,000. Opaleye Management Inc. raised its holdings in Lyell Immunopharma by 334.9% in the second quarter. Opaleye Management Inc. now owns 344,025 shares of the company’s stock worth $4,834,000 after purchasing an additional 264,928 shares in the last quarter. venBio Partners LLC purchased a new stake in shares of Lyell Immunopharma during the second quarter valued at about $4,744,643. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Lyell Immunopharma in the 1st quarter valued at about $959,000. Institutional investors own 66.05% of the company’s stock.
About Lyell Immunopharma
Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.
The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.
See Also
- Five stocks we like better than Lyell Immunopharma
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.
